Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

紫杉醇表达间充质基质细胞（MSCs追踪）可增加其分泌组的抗肿瘤疗效

卷 21, 期 3, 2021

发表于: 16 November, 2020

页: [213 - 222] 页: 10

弟呕挨: 10.2174/1568009620666201116112153

价格: $65

摘要

背景：用肿瘤坏死因子相关的凋亡诱导配体蛋白（MSCs-TRAIL）工程改造的脂肪组织来源的MSC具有显着的抗癌活性。无需任何基因改造的MSC，暴露于高剂量的化学治疗剂就能吸收并释放影响肿瘤增殖的药物。这项研究的目的是通过提供增强的抗肿瘤功效来验证MSCs-TRAIL摄取和释放紫杉醇（PTX）的能力。 方法：采用MTT法检测MSCs和MSCs-TRAIL对紫杉醇（PTX）的敏感性，并按照标准程序对细胞进行PTX加载。通过HPLC分析分泌组中PTX的存在，对可溶性TRAIL（s-TRAIL）进行微阵列分析，并测试其体外抗癌活性。 结果：MSCs-TRAIL对PTX具有抗性，并能够掺入并释放药物。载有PTX的MSCs-TRAIL不会抑制s-TRAIL的分泌，并且如体外在人胰腺癌（CFPAC-1）和胶质母细胞瘤上测试的那样，PTX传递与s-TRAIL分泌一起导致细胞分泌组的抗肿瘤功效增强（ U87-MG）。 结论：我们的结果是首次证明了基于基因操作和药物输送的两种新的MSCs治疗方法。如果在体内得到证实，这可能会增强MSCs-TRAIL的功效，并由于全身性治疗PTX而大大有助于降低毒性。

关键词: TRAIL-间充质基质细胞，药物递送机制，紫杉醇，分泌组，U87-MG，CFPac-1。

« Previous Next »
图形摘要

[1]
Gnecchi, M.; Zhang, Z.; Ni, A.; Dzau, V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res., 2008, 103(11), 1204-1219.
[http://dx.doi.org/10.1161/CIRCRESAHA.108.176826] [PMID: 19028920]
[2]
Biancone, L.; Bruno, S.; Deregibus, M.C.; Tetta, C.; Camussi, G. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol. Dial. Transplant., 2012, 27(8), 3037-3042.
[http://dx.doi.org/10.1093/ndt/gfs168] [PMID: 22851627]
[3]
Patel, D.M.; Shah, J.; Srivastava, A.S. Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int., 2013, 2013, 496218.
[http://dx.doi.org/10.1155/2013/496218] [PMID: 23577036]
[4]
Aronin, C.E.P.; Tuan, R.S. Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells. Birth Defects Res. Part C-Embryo Today-Rev., 2010, 90, 67-74.
[http://dx.doi.org/10.1002/bdrc.20174]
[5]
Zhang, Y.; Yan, W.; Collins, M.A.; Bednar, F.; Rakshit, S.; Zetter, B.R.; Stanger, B.Z.; Chung, I.; Rhim, A.D.; di Magliano, M.P. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res., 2013, 73 (20 ), 6359 -6374 .
[http://dx.doi.org/10.1158/0008-5472.CAN-13-1558-T]
[6]
Li, N.; Hua, J. Interactions between mesenchymal stem cells and the immune system. Cell. Mol. Life Sci., 2017, 74(13), 2345-2360.
[http://dx.doi.org/10.1007/s00018-017-2473-5] [PMID: 28214990]
[7]
Crivelli, B.; Chlapanidas, T.; Perteghella, S.; Lucarelli, E.; Pascucci, L.; Brini, A.T.; Ferrero, I.; Marazzi, M.; Pessina, A.; Torre, M.L. Italian Mesenchymal Stem Cell Group (GISM). Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J. Control. Release, 2017, 262(262), 104-117.
[http://dx.doi.org/10.1016/j.jconrel.2017.07.023] [PMID: 28736264]
[8]
Lin, W.; Huang, L.; Li, Y.; Fang, B.; Li, G.; Chen, L.; Xu, L. Mesenchymal stem cells and cancer: clinical challenges and opportunities. Biomed Res Int., 2019, 8, 8280853.
[9]
Belmar-Lopez, C.; Mendoza, G.; Oberg, D.; Burnet, J.; Simon, C.; Cervello, I.; Iglesias, M.; Ramirez, J.C.; Lopez-Larrubia, P.; Quintanilla, M.; Martin-Duque, P. Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivo effects on migration capacity and tumor growth. BMC Med., 2013, 28 (11 ), 139 .
[10]
Reagan, M.R.; Kaplan, D.L. Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells, 2011, 29(6), 920-927.
[http://dx.doi.org/10.1002/stem.645] [PMID: 21557390]
[11]
Park, J.S.; Suryaprakash, S.; Lao, Y.H.; Leong, K.W. Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods, 2015, 84, 3-16.
[http://dx.doi.org/10.1016/j.ymeth.2015.03.002] [PMID: 25770356]
[12]
Sasportas, L.S.; Kasmieh, R.; Wakimoto, H.; Hingtgen, S.; van de Water, J.A.; Mohapatra, G.; Figueiredo, J.L.B.; Martuza, R.L.; Weissleder, R.; Shah, K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl. Acad. Sci. USA, 2009, 106(12), 4822-4827.
[http://dx.doi.org/10.1073/pnas.0806647106] [PMID: 19264968]
[13]
Shah, K. Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Deliv. Rev., 2012, 64(8), 739-748.
[http://dx.doi.org/10.1016/j.addr.2011.06.010] [PMID: 21740940]
[14]
Stuckey, D.W.; Shah, K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol. Med., 2013, 19(11), 685-694.
[http://dx.doi.org/10.1016/j.molmed.2013.08.007] [PMID: 24076237]
[15]
Sage, E.K.; Thakrar, R.M.; Janes, S.M. Genetically modified mesenchymal stromal cells in cancer therapy. Cytotherapy, 2016, 18(11), 1435-1445.
[http://dx.doi.org/10.1016/j.jcyt.2016.09.003] [PMID: 27745603]
[16]
Niess, H.; von Einem, J.C.; Thomas, M.N.; Michl, M.; Angele, M.K.; Huss, R.; Günther, C.; Nelson, P.J.; Bruns, C.J.; Heinemann, V. Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. BMC Cancer., 2015, 8 (15 ), 237 .
[17]
Schweizer, M.T.; Wang, H.; Bivalacqua, T.J.; Partin, A.W.; Lim, S.J.; Chapman, C.; Abdallah, R.; Levy, O.; Bhowmick, N.A.; Karp, J.M.; De Marzo, A.; Isaacs, J.T.; Brennen, W.N.; Denmeade, S.R. A phase I study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer. Stem Cells Transl. Med., 2019, 8(5), 441-449.
[http://dx.doi.org/10.1002/sctm.18-0230] [PMID: 30735000]
[18]
Nowakowski, A.; Drela, K.; Rozycka, J.; Janowski, M.; Lukomska, B. Engineered mesenchymal stem cells as an anti-cancer trojan horse. Stem Cells Dev., 2016, 25(20), 1513-1531.
[http://dx.doi.org/10.1089/scd.2016.0120] [PMID: 27460260]
[19]
Shi, J.; Zheng, D.; Man, K.; Fan, S.T.; Xu, R. TRAIL: a potential agent for cancer therapy. Curr. Mol. Med., 2003, 3(8), 727-736.
[http://dx.doi.org/10.2174/1566524033479401] [PMID: 14682494]
[20]
Kruyt, F.A. TRAIL and cancer therapy. Cancer Lett., 2008, 263(1), 14-25.
[http://dx.doi.org/10.1016/j.canlet.2008.02.003] [PMID: 18329793]
[21]
Grisendi, G.; Bussolari, R.; Cafarelli, L.; Petak, I.; Rasini, V.; Veronesi, E.; De Santis, G.; Spano, C.; Tagliazzucchi, M.; Barti-Juhasz, H.; Scarabelli, L.; Bambi, F.; Frassoldati, A.; Rossi, G.; Casali, C.; Morandi, U.; Horwitz, E.M.; Paolucci, P.; Conte, P.; Dominici, M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res., 2010, 70(9), 3718-3729.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-1865] [PMID: 20388793]
[22]
Moniri, M.R.; Sun, X.Y.; Rayat, J.; Dai, D.; Ao, Z.; He, Z.; Verchere, C.B.; Dai, L.J.; Warnock, G.L. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther., 2012, 19(9), 652-658.
[http://dx.doi.org/10.1038/cgt.2012.46] [PMID: 22767216]
[23]
Spano, C.; Grisendi, G.; Golinelli, G.; Rossignoli, F.; Prapa, M.; Bestagno, M.; Candini, O.; Petrachi, T.; Recchia, A.; Miselli, F.; Rovesti, G.; Orsi, G.; Maiorana, A.; Manni, P.; Veronesi, E; Piccinno, M.S.; Murgia, A.; Pinelli, M.; Horwitz, E.M.; Cascinu, S.; Conte, P.; Dominici, M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep., 2019, 9(1), 1788.
[http://dx.doi.org/10.1038/s41598-018-37433-6]
[24]
Song, K.; Benhaga, N.; Anderson, R.L.; Khosravi-Far, R. Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res., 2006, 66 (12), 6304-6311.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3501]
[25]
Wang, S.S.; Feng, L.; Hu, B.G.; Lu, Y.F.; Wang, W.M.; Guo, W.; Suen, C.W.; Jiao, B.H.; Pang, J.X.; Fu, W.M.; Zhang, J.F. mir-133a promotes trail resistance in glioblastoma via suppressing death receptor 5 and activating NF-κB signaling. Mol. Ther. Nucleic Acids, 2017, 8(8), 482-492.
[http://dx.doi.org/10.1016/j.omtn.2017.07.015] [PMID: 28918048]
[26]
Pessina, A.; Bonomi, A.; Coccè, V.; Invernici, G.; Navone, S.; Cavicchini, L.; Sisto, F.; Ferrari, M.; Viganò, L.; Locatelli, A; Ciusani, E.; Cappelletti, G.; Cartelli, D.; Arnaldo, C.; Parati, E.; Marfia, G.; Pallini, R.; Falchetti, M.L.; Alessandri, G. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One., 2011, 6 (12 ), 28321 .
[27]
Bonomi, A.; Coccè, V.; Cavicchini, L.; Sisto, F.; Dossena, M.; Balzarini, P.; Portolani, N.; Ciusani, E.; Parati, E.; Alessandri, G.; Pessina, A. Adipose tissue-derived stromal cells primed in vitro with paclitaxel acquire anti-tumor activity. Int. J. Immunopathol. Pharmacol., 2013, 26(1)(Suppl.), 33-41.
[http://dx.doi.org/10.1177/03946320130260S105] [PMID: 24046947]
[28]
Pascucci, L.; Coccè, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Viganò, L.; Locatelli, A.; Sisto, F.; Doglia, S.M.; Parati, E.; Bernardo, M.E.; Muraca, M.; Alessandri, G.; Bondiolotti, G.; Pessina, A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release, 2014, 192(192), 262-270.
[http://dx.doi.org/10.1016/j.jconrel.2014.07.042] [PMID: 25084218]
[29]
Pessina, A.; Leonetti, C.; Artuso, S.; Benetti, A.; Dessy, E.; Pascucci, L.; Passeri, D.; Orlandi, A.; Berenzi, A.; Bonomi, A.; Coccè, V.; Ceserani, V.; Ferri, A.; Dossena, M.; Mazzuca, P.; Ciusani, E.; Ceccarelli, P.; Caruso, A.; Portolani, N.; Sisto, F.; Parati, E.; Alessandri, G. Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. J Exp Clin Cancer Res. , 2015, 13 , 34 -82 .
[30]
Bonomi, A.; Silini, A.; Vertua, E.; Signoroni, P.B.; Coccè, V.; Cavicchini, L.; Sisto, F.; Alessandri, G.; Pessina, A.; Parolini, O. Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study. Stem Cell Res Ther., 2015, 28, 6-155.
[31]
Brini, A.T.; Coccè, V.; Ferreira, L.M.; Giannasi, C.; Cossellu, G.; Giannì, A.B.; Angiero, F.; Bonomi, A.; Pascucci, L.; Falchetti, M.L.; Ciusani, E.; Bondiolotti, G.; Sisto, F.; Alessandri, G.; Pessina, A.; Farronato, G. Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel. Expert Opin. Drug Deliv., 2016, 13(6), 789-798.
[http://dx.doi.org/10.1517/17425247.2016.1167037] [PMID: 26986001]
[32]
Nolta, J.A. “Next-generation” mesenchymal stem or stromal cells for the in vivo delivery of bioactive factors: progressing toward the clinic. Transfusion, 2016, 56(4), 15S-17S.
[http://dx.doi.org/10.1111/trf.13564] [PMID: 27079315]
[33]
Rimoldi, I.; Coccè, V.; Facchetti, G.; Alessandri, G.; Brini, A.T.; Sisto, F.; Parati, E.; Cavicchini, L.; Lucchini, G.; Petrella, F.; Ciusani, E.; Pessina, A. Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines. Biomed. Pharmacother., 2018, 108, 111-118.
[http://dx.doi.org/10.1016/j.biopha.2018.09.040] [PMID: 30218855]
[34]
Scioli, M.G.; Artuso, S.; D'Angelo, C.; Porru, M.; D'Amico, F.; Bielli, A.; Gentile, P.; Cervelli, V.; Leonetti, C.; Orlandi, A. Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. PLoS One., 2018, 13(9), 0203426.
[35]
Rossignoli, F.; Spano, C.; Grisendi, G.; Foppiani, E.M.; Golinelli, G.; Mastrolia, I.; Bestagno, M.; Candini, O.; Petrachi, T.; Recchia, A.; Miselli, F.; Rovesti, G.; Orsi, G.; Veronesi, E; Medici, G.; Petocchi, B.; Pinelli, M.; Horwitz, E.M.; Conte, P.; Dominici, M. MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Theranostics., 2019, 9(2), 436-448.
[36]
Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer, 2013, 49(6), 1374-1403.
[http://dx.doi.org/10.1016/j.ejca.2012.12.027] [PMID: 23485231]
[37]
Di Carlo, D.T.; Cagnazzo, F.; Benedetto, N.; Morganti, R.; Perrini, P. Multiple high-grade gliomas: Epidemiology, management, and outcome. A systematic review and meta-analysis. Neurosurg. Rev., 2017, 1-13.
[PMID: 29138949]
[38]
McIntosh, J.C.; Schoumacher, R.A.; Tiller, R.E. Pancreatic adenocarcinoma in a patient with cystic fibrosis. Am. J. Med., 1988, 85(4), 592.
[http://dx.doi.org/10.1016/S0002-9343(88)80116-5] [PMID: 3177424]
[39]
Schoumacher, R.A.; Ram, J.; Iannuzzi, M.C.; Bradbury, N.A.; Wallace, R.W.; Hon, C.T.; Kelly, D.R.; Schmid, S.M.; Gelder, F.B.; Rado, T.A. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc. Natl. Acad. Sci. USA, 1990, 87(10), 4012-4016.
[http://dx.doi.org/10.1073/pnas.87.10.4012] [PMID: 1692630]
[40]
Fogh, J.; Fogh, J.M.; Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst., 1977, 59(1), 221-226.
[http://dx.doi.org/10.1093/jnci/59.1.221] [PMID: 327080]
[41]
Olopade, O.I.; Jenkins, R.B.; Ransom, D.T.; Malik, K.; Pomykala, H.; Nobori, T.; Cowan, J.M.; Rowley, J.D.; Diaz, M.O. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res., 1992, 52(9), 2523-2529.
[PMID: 1568221]
[42]
Ceserani, V.; Ferri, A.; Berenzi, A.; Benetti, A.; Ciusani, E.; Pascucci, L.; Bazzucchi, C.; Coccè, V.; Bonomi, A.; Pessina, A.; Ghezzi, E.; Zeira, O.; Ceccarelli, P.; Versari, S.; Tremolada, C.; Alessandri, G. Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells. Vasc. Cell, 2016, 8, 3.
[http://dx.doi.org/10.1186/s13221-016-0037-3] [PMID: 27547374]
[43]
Coccè, V.; Brini, A.; Giannì, A.B.; Sordi, V.; Berenzi, A.; Alessandri, G.; Tremolada, C.; Versari, S.; Bosetto, A.; Pessina, A. A nonenzymatic and automated closed-cycle process for the isolation of mesenchymal stromal cells in drug delivery applications. Stem Cells Int., 2018, 2018(20), 4098140.
[http://dx.doi.org/10.1155/2018/4098140] [PMID: 29531535]
[44]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[45]
Pessina, A.; Gribaldo, L.; Mineo, E.; Neri, M.G. In vitro short-term and long-term cytotoxicity of fluoroquinolones on murine cell lines. Indian J. Exp. Biol., 1994, 32(2), 113-118.
[PMID: 8045610]
[46]
Reed, L.J.; Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg., 1938, 27, 493-497.
[47]
Mariotti, M.; Colognato, R.; Rimoldi, M.; Rizzetto, M.; Sisto, F.; Coccè, V.; Bonomi, A.; Parati, E.; Alessandri, G.; Bagnati, R.; Pessina, A. Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity. Anticancer. Agents Med. Chem., 2015, 15(3), 400-405.
[http://dx.doi.org/10.2174/1871520614666140618113441] [PMID: 24942547]
[48]
Bosco, D.B.; Kenworthy, R.; Zorio, D.A.; Sang, Q.X. Human mesenchymal stem cells are resistant to Paclitaxel by adopting a non-proliferative fibroblastic state. PLoS One, 2015, 10(6), e0128511.
[http://dx.doi.org/10.1371/journal.pone.0128511] [PMID: 26029917]
[49]
Gyamfi, J.; Eom, M.; Koo, J.S.; Choi, J. Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction. Transl. Oncol., 2018, 11(2), 275-285.
[http://dx.doi.org/10.1016/j.tranon.2017.12.009] [PMID: 29413760]
[50]
Zhang, B.; Yin, Y.; Lai, R.C.; Tan, S.S.; Choo, A.B.; Lim, S.K. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev. , 2014, 23 (11 ), 1233 -44 .
[http://dx.doi.org/10.1089/scd.2013.0479]
[51]
Shan, Y.; He, X.; Song, W.; Han, D.; Niu, J.; Wang, J. Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med. , 2015, 8(6), 9114-9120.
[52]
Pascucci, L.; Coccè, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Viganò, L.; Locatelli, A.; Sisto, F.; Doglia, S. M.; Parati, E.; Bernardo, M. E.; Muraca, M.; Alessandri, G.; Bondiolotti, G.; Pessina, A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release, 2014, 192, 262-270.
[http://dx.doi.org/10.1016/j.jconrel.2014.07.042]
[53]
Coccè, V.; Franzè, S.; Brini, A.T.; Giannì, A.B.; Pascucci, L.; Ciusani, E.; Alessandri, G.; Farronato, G.; Cavicchini, L.; Sordi, V.; Paroni, R.; Dei Cas, M.; Cilurzo, F.; Pessina, A. In Vitro Anticancer Activity of Extracellular Vesicles (EVs) Secreted by Gingival Mesenchymal Stromal Cells Primed with Paclitaxel. Pharmaceutics, 2019, 11(2), 61.
[http://dx.doi.org/10.3390/pharmaceutics11020061] [PMID: 30717104]
[54]
Sage, E.K.; Kolluri, K.K.; McNulty, K.; Lourenco, Sda.S.; Kalber, T.L.; Ordidge, K.L.; Davies, D.; Gary Lee, Y.C.; Giangreco, A.; Janes, S.M. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax, 2014, 69(7), 638-647.
[http://dx.doi.org/10.1136/thoraxjnl-2013-204110] [PMID: 24567297]

Rights & Permissions Print Cite
Article Metrics
74
© 2024 Bentham Science Publishers | Privacy Policy